MediWound (MDWD) vs Nkarta (NKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nkarta (NKTX) has outperformed MediWound (MDWD) over the past year, gaining 6.2% versus a loss of 29.5%. Over five years, MDWD leads with a -48.0% price change compared with -87.9% for NKTX. MediWound is the larger company by market cap ($160.3 million vs $159.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDWD | NKTX |
|---|---|---|
| Share price | $12.42 | $2.22 |
| Market cap | $160.35M | $159.01M |
| 1-day change | -3.35% | -2.20% |
| YTD return | -32.72% | +20.00% |
| 1-year return | -29.53% | +6.22% |
| 5-year return | -47.97% | -87.90% |
| EPS (TTM) | $-2.17 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.03 | $3.72 |
| 52-week low | $12.42 | $1.70 |
| Distance from 52-week high | -37.99% | -40.32% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +146.94% | +387.84% |
| Average volume | 84.67K | 613.16K |
| Shares outstanding | 12.91M | 71.62M |
| Employees | 121 | 106 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NKTX has outperformed MDWD by 35.8 percentage points over the past year.
About MediWound
MDWD stock →MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Health Care · Medicinal Chemicals and Botanical Products · 121 employees
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
MDWD vs NKTX FAQ
Which is bigger, MediWound or Nkarta?
MediWound (MDWD) is larger, with a market capitalization of $160.35M compared with $159.01M for Nkarta (NKTX).
Which stock has performed better over the past year, MDWD or NKTX?
NKTX returned +6.22% over the past 12 months, compared with -29.53% for MDWD (price return, excluding dividends). Past performance does not predict future results.
Are MediWound and Nkarta in the same industry?
Both are in the Health Care sector, but in different industries: Medicinal Chemicals and Botanical Products for MediWound and Biotechnology: Pharmaceutical Preparations for Nkarta.